2023-03-24 18:22:48 ET
- Iovance Biotherapeutics ( NASDAQ: IOVA ) is up 13% in after-hours trading Friday after reporting it has completed its rolling Biologics License Application for lifileucel for melanoma.
- Lifileucel, a tumor infiltrating lymphocyte therapy, is under investigation for patients with advanced melanoma that have failed on anti-PD-1/L1 therapy and targeted therapy.
- There are no approved treatments for melanoma in this setting .
- Read why Seeking Alpha contributor BioSci Capital Partners reiterated a strong buy rating for Iovance ( IOVA ) in February.
For further details see:
Iovance up 13% on completing Biologics License Application submission for lifileucel